imeglimin

Poxel pivots to different programs, but questions abound over imeglimin
Fierce Biotech
Mon, 07/12/21 - 10:46 am
Poxel
NASH
diabetes
imeglimin
Vivek Ramaswamy’s Metavant hits a brick wall, abandoning a lead program for diabetes. And there’s nothing visible left to see here
Endpoints
Fri, 11/20/20 - 11:20 am
Metavant
diabetes
Vivek Ramaswamy
imeglimin
Poxel posts phase 3 diabetes data ahead of approval decision
Fierce Biotech
Thu, 09/24/20 - 10:14 am
Poxel
diabetes
clinical trials
imeglimin
Japan
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Pharmaforum
Wed, 04/10/19 - 11:40 pm
Poxel
Japan
diabetes
type 2 diabetes
clinical trials
imeglimin
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Endpoints
Mon, 10/30/17 - 11:05 am
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel